论文部分内容阅读
三甲氧苄氨嘧啶(TMP)加磺胺甲基异恶唑(SMZ)的临床应用已六年余,经各国广泛试用,此合剂对多种感染具有疗效高、服用方便、毒性反应小等优点。我国现已生产和应用此合剂,也称复方新诺明,即 TMP0.08加 SMZ0.4片剂及针剂。为了认识和防止此合剂的不良反应,本文仅就其临床应用的毒副反应综述如下,供临床应用时参考。
The clinical application of trimethoprim (SMP) and sulfamethoxazole (SMZ) has been more than six years and has been extensively tested in various countries. The combination has the advantages of high curative effect, convenient administration and low toxicity to various infections. China now has the production and application of this mixture, also known as cotrimoxazole, that is, TMP0.08 plus SMZ0.4 tablets and injections. In order to recognize and prevent this combination of adverse reactions, this article only on the clinical application of toxicity as outlined below, for clinical reference.